Omeros(OMER) - 2024 Q1 - Earnings Call Transcript

Thank you, Jennifer, and good afternoon, everyone. I'm joined on today's call by Mike Jacobsen, Nadia Dac, Andreas Grauer, Kathy Melty, and Steve Whitaker, collectively representing our finance, commercial, clinical, and regulatory functions. Our three trials in our OMS-906 Phase 2 clinical program in PNH are progressing well. The first evaluating OMS-906 and PNH patients, who have not previously been treated with a complement inhibitor, in other words, complement inhibitor naïve, has fully enrolled and is ...